Dendritic cells vaccines: Immunotherapy against cancer
1 Pharmacy School, University of Costa Rica, San José, Costa Rica.
2 Institute of Pharmaceutical Research (INIFAR), San José, Costa Rica.
Review Article
GSC Biological and Pharmaceutical Sciences, 2020, 12(01), 205-215.
Article DOI: 10.30574/gscbps.2020.12.1.0199
Publication history:
Received on 22 June 2020; revised on 19 July 2020; accepted on 22 July 2020
Abstract:
Dendritic cells are specialized cells of the innate immune system, with high capacity to present antigens in the context of the Major Histocompatibility Complex II (MHC-II) to T lymphocytes (CD4+); these cells are up to 100 times stronger than any other antigen presenting cell. The ability of the antigen presentation by dendritic cells has been documented in animal models and clinical studies conducted in humans. Based on the above, different techniques and methods have been developed to use dendritic cells in cancer-aimed immunotherapies. The dendritic cell vaccines refer to biological therapies, prepared by different strategies (ex vivo and in vivo), which aim to enhance the presentation of tumor antigens and develop a more targeted and sustained immune response on these. They are obtained from precursor cells that mature with specific stimuli that direct them to the desired therapy. Different applications for these therapies have been described in numerous types of cancers, which will be described.
Keywords:
Dendritic cell; Cancer; Vaccine; Immune; Tumor
Full text article in PDF:
Copyright information:
Copyright © 2020 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
